Review of Utility Values for Economic Modeling in Type 2 Diabetes

被引:194
作者
Beaudet, Amelie [1 ]
Clegg, John [1 ]
Thuresson, Per-Olof [1 ]
Lloyd, Adam [2 ]
McEwan, Phil [3 ]
机构
[1] IMS Hlth, CH-4051 Basel, Switzerland
[2] IMS Hlth, London, England
[3] Swansea Univ, Ctr Hlth Econ, Swansea, W Glam, Wales
关键词
diabetes; EQ-5D; quality of life; systematic review; utility; QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; HEALTH-RELATED UTILITY; COST-UTILITY; COMPLICATIONS; HYPOGLYCEMIA; IMPACT; STATES; ASSOCIATIONS; VALUATIONS;
D O I
10.1016/j.jval.2014.03.003
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Economic analysis in type 2 diabetes mellitus (T2DM) requires an assessment of the effect of a wide range of complications. The objective of this article was to identify a set of utility values consistent with the National Institute for Health and Care Excellence (NICE) reference case and to critically discuss and illustrate challenges in creating such a utility set Methods: A systematic literature review was conducted to identify studies reporting utility values for relevant complications. The methodology of each study was assessed for consistency with the NICE reference case. A suggested set of utility values applicable to modeling was derived, giving preference to studies reporting multiple complications and correcting for comorbidity. Results: The review considered 21 relevant diabetes complications. A total of 16,574 articles were identified; after screening, 61 articles were assessed for methodological quality. Nineteen articles met NICE criteria, reporting utility values for 20 of 21 relevant complications. For renal transplant, because no articles meeting NICE criteria were identified, two articles using other methodologies were included. Index value estimates for T2DM without complication ranged from 0.711 to 0.940. Utility decrement associated with complications ranged from 0.014 (minor hypoglycemia) to 0.28 (amputation). Limitations associated with the selection of a utility value for use in economic modeling included variability in patient recruitment, heterogeneity in statistical analysis, large variability around some point estimates, and lack of recent data Conclusions: A reference set of utility values for T2DM and its complications in line with NICE requirements was identified. This research illustrates the challenges associated with systematically selecting utility data for economic evaluations.
引用
收藏
页码:462 / 470
页数:9
相关论文
共 43 条
[21]   A study of the quality of life and cost-utility of renal transplantation [J].
Laupacis, A ;
Keown, P ;
Pus, N ;
Krueger, H ;
Ferguson, B ;
Wong, C ;
Muirhead, N .
KIDNEY INTERNATIONAL, 1996, 50 (01) :235-242
[22]   Health-Related Quality of Life Using the EuroQol 5D Questionnaire in Korean Patients with Type 2 Diabetes [J].
Lee, Woo Je ;
Song, Kee-Ho ;
Noh, Jung Hyun ;
Choi, Yon Jong ;
Jo, Min-Woo .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (03) :255-260
[23]   Health utility values associated with diabetic retinopathy [J].
Lloyd, A. ;
Nafees, B. ;
Gavriel, S. ;
Rousculp, M. D. ;
Boye, K. S. ;
Ahmad, A. .
DIABETIC MEDICINE, 2008, 25 (05) :618-624
[24]   A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation [J].
Lung, Tom W. C. ;
Hayes, Alison J. ;
Hayen, Andrew ;
Farmer, Andrew ;
Clarke, Philip M. .
QUALITY OF LIFE RESEARCH, 2011, 20 (10) :1669-1678
[25]   Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain [J].
Marrett, E. ;
Stargardt, T. ;
Mavros, P. ;
Alexander, C. M. .
DIABETES OBESITY & METABOLISM, 2009, 11 (12) :1138-1144
[26]   Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change [J].
Matza, Louis S. ;
Yurgin, Nicole ;
Boye, Kristina S. ;
Malley, Karen ;
Shorr, Jodi M. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (09) :2051-2062
[27]   Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) [J].
McEwan, P ;
Peters, JR ;
Bergenheim, K ;
Currie, CJ .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (01) :121-129
[28]  
National Institute for Health and Care Excellence, 2012, SINGL TECHN APPR STA
[29]   Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada [J].
O'Reilly, Daria J. ;
Xie, Feng ;
Pullenayegum, Eleanor ;
Gerstein, Hertzel C. ;
Greb, Janet ;
Blackhouse, Gord K. ;
Tarride, Jean-Eric ;
Bowen, Jim ;
Goeree, Ron A. .
QUALITY OF LIFE RESEARCH, 2011, 20 (06) :939-943
[30]   The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making [J].
Palmer, AJ ;
Roze, S ;
Valentine, WJ ;
Minshall, ME ;
Foos, V ;
Lurati, FM ;
Lammert, M ;
Spinas, GA .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 :S5-S26